Atlas Trials

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Clinical trial NCT03258554 · COMPLETED

Trial details

NCT number
NCT03258554
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Head and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell CarcinomaLaryngeal Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaPathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Squamous Cell Carcinoma of Unknown PrimaryStage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Start date
2018-04-03
Primary completion
2022-09-20
Enrollment
196

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.